NEWSROOM

PRESS RELEASES

Aristea Therapeutics

June 30, 2022
Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

SAN DIEGO, June 30, 2022 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced it has dosed its first subject in the open-label extension (OLE) for its Phase 2b trial of RIST4721 in palmoplantar pustulosis (PPP), a rare dermatological condition. read more →

March 28, 2022
Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

SAN DIEGO, March 28, 2022 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the dosing of the first patient in its Phase 2b trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of palmoplantar pustulosis (PPP), a rare inflammatory skin disorder. read more →

IN THE NEWS

Empowered Patient Podcast

August 2, 2022
Treating Inflammatory Diseases by Blocking Neutrophils Moving from Bone Marrow

James Mackay is the Founder, President, and CEO of Aristea Therapeutics, a San Diego-based company that is applying its insights on neutrophils to develop a treatment for a rare inflammatory skin condition known as palmoplantar pustulosis, PPP. Most of the people who get this disease are postmenopausal females, and 90%+ of the patients either are current cigarette smokers or have a history of cigarette smoking. read more →

Tech Nation Radio Podcast

July 15, 2022
Tech Visionary – No Tech

Dr. James Mackey, the President & CEO, Aristea Therapeutics, tells about a painful disease which affects the palms of hand and soles of feet in post-menopausal women - Palmoplantar pustulosis or PPP - and how it may relate to other diseases. read more →

EVENTS

7th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
October 7, 2022

The SHSA will be held October 7-9, 2022, at the Intercontinental Miami, jointly hosted by the Hidradenitis Suppurativa Foundation (HSF) and the Canadian Hidradenitis Suppurativa Foundation (CHSF). Aristea Therapeutics is a sponsor of this year's event. read more →

ACR Convergence 2022
November 10, 2022

Aristea participating at ACR Convergence 2022. read more →

PRESENTATIONS